Shrestha, Niraj
Dee, Michael J.
Chaturvedi, Pallavi
Leclerc, Gilles M.
Mathyer, Mary
Dufour, Celeste
Arthur, Laura
Becker-Hapak, Michelle
Foster, Mark
McClain, Ethan
Pena, Natalia Valderrama
Kage, Karen
Zhu, Xiaoyun
George, Varghese
Liu, Bai
Egan, Jack
Echeverri, Christian
Wang, Meng
You, Lijing
Kong, Lin
Li, Liying
Berrien-Elliott, Melissa M.
Cooper, Matthew L.
Fehniger, Todd A.
Rhode, Peter R.
Wong, Hing C.
Funding for this research was provided by:
HCW Biologics
Wugen
NIH (P50CA171963, P50CA171963, P50CA171963, P50CA171963, P50CA171963)
Paula C and Rodger O. Riney Blood Cancer Initiative
Article History
Received: 7 March 2024
Accepted: 19 June 2024
First Online: 3 July 2024
Declarations
:
: HCW, PRR, NS, MD, PC, GML, NVP, XZ, VG, BL, LK, KK, CAE, LY, LL, JOE, and MW are employees or have equity in HCW Biologics Inc. MM, CD, LA, and MC are employees and have equity in Wugen. MMBE, TAF have equity, consulting, licensed patents with potential future royalties in Wugen Inc. TAF serves on the SAB of Wugen, Indapta Therapeutics, Orca Bio, and Affimed, and has research funding from HCW Biologics, Affimed, Wugen. TAF is an advisor for AI Proteins, Smart Immune.